Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn maintains an Overweight rating on Royalty Pharma (NASDAQ:RPRX) and raises the price target from $54 to $57.
November 09, 2023 | 2:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on Royalty Pharma and raises the price target from $54 to $57, indicating a positive outlook for the company.
The raised price target by Morgan Stanley indicates a positive outlook for Royalty Pharma. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100